Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Is a "Vanishing Tumor" Always a Lymphoma?
Neurol 59:762-764, Bromberg,J.E.C.,et al, 2002
Assessment of Normal-Appearing White and Gray Matter in Patients with Primary Progressive Multiple Sclerosis
Arch Neurol 59:1406-1412, Rovaris,M.,et al, 2002
Proton MR Spectroscopy of Tumefactive Demyelinating Lesions
AJNR 23:1378-1386, Saindane,A.M.,et al, 2002
Acute Disseminated Encephalomyelitis
Neurol 59:1224-1231, Tenembaum,S.,et al, 2002
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group
Neurol 59:998-1005, CHAMPS Study Group, 2002
Therapy-Related Acute Myeloblastic Leukemia After Mitoxantrone Treatment in a Patient with MS
Neurol 59:954-955, Brassat,D.,et al, 2002
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Prognosis for Gross Motor Function in Cerebral Palsy
JAMA 288:1357-1363,1399, Rosenbaum,P.L., et al, 2002
A Blinding Combination
Lancet 360:1220, Matthews,B.N.,et al, 2002
Outcome of and Prognostic Factors for Herpes Simplex Encephalitis in Adult Patients: Results of a Multicenter Study
Clin Inf Dis 35:254-260, Raschillas, F.,et al, 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Phenylketonuria Presenting in Adulthood as Progressive Spastic Paraparesis With Dementia
JNNP 71:795-797, Kasim,S.,et al, 2001
Surgical Therapy for Tremor in Multiple Sclerosis
Neurol 57:1876-1882, Matsumoto,J.,et al, 2001
Problems With Diagnositc Criteria for Multiple Sclerosis
Lancet 358:1746-1747, Poser,C.M. &Brinar,V.V., 2001
La Crosse Encephalitis in Children
NEJM 344:801-807, McJunkin,J.E.,et al, 2001
Seizures in Multiple Sclerosis
Epilepsia 42:72-79, Sokic,D.V.,et al, 2001
European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients wi
Ann Neurol 49:290-297, Comi,G.,et al, 2001
The Influence of Cognitive Impairment on Driving Performance in Multiple Sclerosis
Neurol 56:1089-1094, Schultheis,M.R.,et al, 2001
CSF Oligoclonal Bands in MS Include Antibodies Against Chlamydophila Antigens
Neurol 56:1168-1176,1126,1128,1130, Yao,S.,et al, 2001
Presence of Chlamydia pneumoniae DNA in the Cerebral Spinal Fluid is a Common Phenomenon in a Variety of Neurological Diseases and Not Restricted to Multiple Sclerosis
Ann Neurol 49:585-589,556, Gieffers,J.,et al, 2001
Disability and Quality of Life in Charcot-Marie-Tooth Disease Type 1
JNNP 70:548-550, Pfeiffer,G.,et al, 2001
Evolution of Cerebral Infarct Volume Assessed by Diffusion-Weighted Magnetic Resonance Imaging
Arch Neurol 58:613-617, Lansberg,M.,G.,et al, 2001
Diffusion-Weighted Imaging and National Institutes of Health Stroke Scale in the Acute Phase of Posterior-Circulation Stroke
Arch Neurol 58:621-628, Linfante,I.,et al, 2001
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Clinical and Neuroradiologic Features of Acute Disseminated Encephalomyelitis in Children
Neurol 56:1308-1312,1257, Hynson,J.L.,et al, 2001
Effect of Early Interferon Treatment on Conversion to Definite Multiple Sclerosis: A Randomised Study
Lancet 357:1576-1582,1547, Comi,G.,et al, 2001
Clinical Presentation of Left Atrial Cardiac Myxoma
Medicine 80:159-172, Pinede,L.,et al, 2001
Acute Disseminated Encephalomyelitis
Neurol 56:1313-1318,1257, Schwarz,S.,et al, 2001
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
Acute Motor Radiculopathy as a First Symptom of MS: Anatomic-radiologic Correlation
Neurol 56:1603-1604, Lavallee,P.,et al, 2001
Autologous Hematopoietic Stem Cell Transplantation Suppresses Gd-enhanced MRI activity in MS
Neurol 57:62-68, Mancardi,G.L.,et al, 2001
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Handicap After Acute Whiplash Injury
Neurol 56:1637-1643, Kasch,H.,et al, 2001
A Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions
Ann Neurol 49:793-796, Bitsch,A.,et al, 2001
Return to Driving After Head Injury
JNNP 70:761-766, Hawley,C.A., 2001
A Three-item Scale for the Early Prediction of Stroke Recovery
Lancet 357:2095-2099, Baird,A.E.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Narcolepsy Associated with Other Central Nervous System Disorders
Neurol 57:539-541, Malik,S.,et al, 2001
14-3-3 Protein in the CSF as Prognostic Marker in Early Multiple Sclerosis
Neurol 57:722-724, Martinez-Yelamos,A.,et al, 2001
MRI Characteristics of the MLF in MS Patients with Chronic Internuclear Ophthalmoparesis
Neurol 57:762-768, Frohman,E.M.,et al, 2001
The Prevalence of Sjogren Syndrome in Patients with Primary Progressive Multiple Sclerosis
Neurol 57:1359-1363,1357, de Seze,J.,et al, 2001
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Arch Neurol 58:2044-2045, Avasarala,J.R.,et al, 2001